Vol. 52 | No. 2 | July-December 2024 Back

Open Access

“Red Flags”: Case Report of Cardiac Amyloidosis with Significant Coronary Artery Disease

Loren D.C. Gabayeron, Cesar Antonio V. Zulueta, Carlo Cortez, Christie Anne Pabelico, Allen Richard Villanueva, Marianne Aludino, Czarina Mae Reyes
Nov 2024 DOI 10.69944/pjc.0344b10d3c

Abstract

BACKGROUND: Cardiac Amyloidosis is a disorder of protein misfolding and metabolism in which insoluble fibrils are deposited in the myocardial extracellular matrix causing organ dysfunction and eventually death. It can exhibit cardiac signs and symptoms, or it can be identified through screening in patients who exhibit extracardiac symptoms of amyloidosis. As there were no clear clinical signs of cardiac amyloidosis and a biopsy is required to show amyloid deposition, the condition has been historically challenging to diagnose. Thus, a high index of suspicion based on the clinical presentation and the outcomes of the preliminary testing arecrucial to determine the approach to diagnosis.

CASE SUMMARY: We outline a case of 75-year-old Filipino male who was admitted due to progressive exertional dyspnea. Cardiac Amyloidosis was considered due to evaluation findings of heart failure with preserved ejection fraction with restrictive type of cardiomyopathy. This was subsequently confirmed through extracardiac fat pad biopsy, echocardiographic strain analysis and Technetium (99mTc) Pyrophosphate (PYP) single photon emission computed tomography scan (SPECT).

CONCLUSION: This case report discussed the red flags of clinical manifestations of cardiac amyloidosis and highlighted the use of non-invasive diagnostic modalities to diagnose the disease. Cardiac amyloidosis remains a rare entity and with emerging therapies that have the potential to improve patient outcomes, early diagnosis is really important. Having high index of suspicion based on signs and symptoms can lead to early detection and an increased number of patients being referred for treatment.

References
  1. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021;42:3599–3726. doi: 10.1093/eurheartj/ehab368.
  2. Falk RH, Alexander KM, Liao R, Dorbala S., et al.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol 2016; 68:1323.
  3. Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol 2015; 24:343-350 [PMID: 26361138 DOI: 10.1016/j.carpath.2015.07.008]
  4. G. Merlini, A. Dispenzieri, V. Sanchorawala et al., “Systemic immunoglobulin light chain amyloidosis,” Nature Reviews Disease Primers, vol. 4, no. 1, 2018.
  5. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice.JACC Heart Failure.2019;7:709–716.
  6. Donnelly JP and Hanna M. Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med 2017; 84: 12-26 [PMID: 29257735 DOI: 10.3949/ccjm.84.s3.02]
  7. M. Rosenzweig and H. Landau, “Light chain (AL) amyloidosis: update on diagnosis and management,” Journal of Hematology and Oncology, vol. 4, no. 1, 2011.
  8. D. Phelan, P. Collier and P. Thavendiranathan. “Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis,” Heart, vol. 98, no. 19, pp. 1442–1448, 2012.
  9. Theresa A McDonagh, Marco Metra, Marianna Adamo & Roy S Gardner, et al. ESC Scientific Document Group , 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599–3726, https://doi.org/10.1093/eurheartj/ehab368
  10. Dohrn MF, Ihne S, Hegenbart U, et al. Targeting transthyretin - Mechanism-based treatment approaches and future perspectives in hereditary amyloidosis. J Neurochem 2021; 156:802.
License

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.